Literature DB >> 19200774

Inhibitory effect of neoadjuvant chemotherapy on metastasis of oral squamous cell carcinoma in a mouse model.

Shuichi Kawashiri1, Natsuyo Noguchi, Akira Tanaka, Hiromitsu Nakaya, Koroku Kato, Etsuhide Yamamoto.   

Abstract

The presence or absence of metastasis bears an important influence on the prognosis of head and neck cancer patients. Neoadjuvant chemotherapy has become widely employed as an initial treatment. However, the actual effectiveness of neoadjuvant chemotherapy on metastasis is still unestablished. Therefore, using an orthotopic implantation model in which cervical lymph node metastasis of oral squamous cell carcinoma can be reproduced, we investigated the inhibitory effect of neoadjuvant chemotherapy on metastasis. A highly invasive and metastatic human oral squamous cell carcinoma cell line, OSC-19 cells, was implanted into the tongues of nude mice. After implantation, the mice were divided into four groups: S (surgery), C+S (preoperative chemotherapy+surgery), S+C (surgery+postoperative chemotherapy), and a control (nontreatment) groups. The treatment (tumor resection or chemotherapy) was started 7 days postimplantation. The effects of each treatment on cervical lymph node metastasis were investigated by examining the rate of lymph node metastasis formation at 28 days postimplantation. In the control group, five of the 11 mice died of cachexia before the end of the experiment. However, all mice in the S, C+S, and S+C groups survived until 28 days after implantation. The cervical lymph node metastasis rates were 81.8% in S, 18.1% in C+S, 63.6% in S+C, and 100% in control groups. Thus, metastasis to the cervical lymph node was markedly inhibited by the combination of neoadjuvant chemotherapy and tumor resection. The findings of this study indicate that neoadjuvant chemotherapy is effective for inhibiting metastasis, and that it is necessary to begin chemotherapy as early as possible to achieve an inhibitory effect on metastasis. Considering these effects, if anticancer drugs are used, better therapeutic results can be expected.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200774     DOI: 10.1016/j.oraloncology.2008.12.003

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

1.  Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy.

Authors:  Yadong Li; Jinsong Zhang
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Outcomes after up-front surgery and metronomic neoadjuvant chemotherapy with S-1 or UFT for early tongue squamous cell carcinoma.

Authors:  Shinichiro Kina; Toshiyuki Nakasone; Takao Kinjo; Fumikazu Nimura; Nao Sunagawa; Akira Arasaki
Journal:  Clin Oral Investig       Date:  2018-10-13       Impact factor: 3.573

Review 3.  A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment.

Authors:  Loredana G Marcu; E Yeoh
Journal:  J Cancer Res Clin Oncol       Date:  2009-07-30       Impact factor: 4.553

Review 4.  Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma.

Authors:  Zhen-Ge Lei; Xiao-Hua Ren; Sha-Sha Wang; Xin-Hua Liang; Ya-Ling Tang
Journal:  Onco Targets Ther       Date:  2016-01-27       Impact factor: 4.147

5.  Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Authors:  Yutaka Kobayashi; Hiroko Kitahara; Mariko Hirai; Akira Tanaka; Rei Jokaji; Kazuhiko Kobayashi; George Bou-Gharios; Hiroyuki Nakamura; Shuichi Kawashiri
Journal:  Oncol Lett       Date:  2019-03-19       Impact factor: 2.967

6.  Inhibition effect of miR-150 on the progression of oral squamous cell carcinoma by data analysis model based on independent sample T-test.

Authors:  Cui Wu; Min Yang; Hengwen Chen
Journal:  Saudi J Biol Sci       Date:  2019-11-27       Impact factor: 4.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.